Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc
Journal website https://gr.elmerpub.com

Original Article

Volume 000, Number 000, January 2026, pages 000-000

Clinical Efficacy of Early and Late Vedolizumab or Infliximab Interventions in Moderate Ulcerative Colitis: A Multicenter, Retrospective Cohort Study

Figures

Figure 1.
Figure 1. Study flowchart of patients included in analysis.
Figure 2.
Figure 2. Proportion of patients in steroid-free remission at week 14 and week 52 stratified by therapeutic strategy (a). Proportion of patients in clinical remission at week 14 and week 52 stratified by therapeutic strategy (b). Proportion of patients in mucosal healing at week 14 and week 52 stratified by therapeutic strategy (c).
Figure 3.
Figure 3. Kaplan-Meier curves of time to clinical remission stratified by therapeutic strategy.

Tables

Table 1. Population Characteristics at Baseline Stratified by Treatment Strategy
 
Baseline matching variablesLate (n = 64)Early (n = 60)P value
ALB: albumin; BMI: body mass index; ESR: erythrocyte sedimentation rate; Hb: hemoglobin; hs-CRP: hypersensitive C-reactive protein; IFX: infliximab; IQR: interquartile range; PLT: blood platelet; SD: standard deviation; VDZ: vedolizumab.
Gender, male, n(%)40 (62.5%)39 (65.0%)0.772
Age, years, median (IQR)47.0 (30.3 - 58.0)40.5 (32.0 - 56.8)0.687
BMI, kg/m2, mean ± SD20.5 ± 3.221.1 ± 3.20.310
History of smoking, n (%)16 (25.0%)13 (21.7%)0.661
Extraintestinal manifestation, n (%)1 (1.6%)4 (6.7%)0.324
Disease extent, n (%)0.310
  E227 (42.2%)20 (33.3%)
  E337 (57.8%)40 (66.7%)
Mayo score, median (IQR)8.0 (6.3 - 9.0)8.0 (7.0 - 9.0)0.224
ESR, mm/h, median (IQR)20.5 (6.1 - 37.9)26.5 (11.5 - 38.8)0.261
hs-CRP, mg/L, median (IQR)4.6 (0.7 - 11.4)5.5 (1.9 - 37.7)0.089
PLT, × 109/L, median (IQR)261.0 (209.3 - 338.3)301.5 (214.3 - 406.0)0.224
Hb, g/L, median (IQR)125.0 (110.5 - 139.5)127.0 (107.0 - 138.0)0.818
ALB, g/L, median (IQR)40.3 (36.3 - 44.8)38.5 (32.2 - 43.5)0.103
Biologics in treatment, n (%)0.953
  VDZ27 (42.2%)25 (41.7%)
  IFX37 (57.8%)35 (58.3%)
Concomitant medications, n (%)
  Steroid7 (10.9%)5 (8.3%)0.624
  Immunosuppressant12 (18.8%)6 (10.0%)0.167

 

Table 2. Mayo score, inflammatory index and nutritive index at week 14.
 
LateEarlyP value
ALB: albumin; ESR: erythrocyte sedimentation rate; Hb: hemoglobin; hs-CRP: hypersensitive C-reactive protein; IQR: interquartile range; PLT: blood platelet.
Mayo score, median (IQR)3.0 (2.0 - 6.0)2.0 (1.0 - 5.8)0.266
ESR, mm/h, median (IQR)9.0 (5.0 - 27.0)7.0 (5.0 - 15.0)0.276
hs-CRP, mg/L, median (IQR)1.3 (0.5 - 6.3)0.9 (0.5 - 3.0)0.110
PLT, × 109/L, median (IQR)217.0 (178.5 - 313.0)223.5 (183.0 - 283.0)0.993
Hb, g/L, median (IQR)132.0 (115.5 - 145.5)130.5 (116.0 - 149.0)0.910
ALB, g/L, median (IQR)43.1 (39.6 - 46.6)44.2 (40.9 - 47.4)0.360

 

Table 3. Assessment at Follow-Up Endpoint
 
LateEarly
Treatment discontinuance
  Symptom improvement13
  Allergic reaction12
  Infection11
  Secondary nonresponse1-
Change medication
  Treatment failure37
  Abnormal liver function-1
Loss to follow-up1612
Colectomy11
At the end of follow-up but less than 52 weeks36

 

Table 4. Mayo Score, Inflammatory Index, and Nutritive Index at Week 52
 
LateEarlyP value
ALB: albumin; ESR: erythrocyte sedimentation rate; hs-CRP: hypersensitive C-reactive protein; Hb: hemoglobin; IQR: interquartile range; PLT: blood platelet; SD: standard deviation.
Mayo score, median (IQR)2.0 (1.0 - 5.0)2.0 (1.0 - 4.0)0.737
ESR, mm/h, median (IQR)13.0 (8.0 - 22.0)6.0 (4.0 - 11.0)0.021
hs-CRP, mg/L, median (IQR)1.1 (0.5 - 5.6)1.0 (0.5 - 4.6)0.738
PLT, × 109/L, median (IQR)215.5 (174.8 - 319.0)245.5 (191.8 - 283.5)0.802
Hb, g/L, median (IQR)138.5 (119.3 - 149.8)147.0 (134.5 - 155.5)0.118
ALB, g/L, mean ± SD43.3 ± 4.743.9 ± 3.20.672